Originally published byEU-Startups
En Carta Diagnostics, a Paris-based DeepTech startup developing a new generation of molecular diagnostics for use at home, has announced the first closing of €5 million in financing. This closing includes €3 million in equity led by Blue Forest Ventures with participation from Ring Capital and existing investors CentraleSupélec Venture, 50 Partners Health, and a […]
The post En Carta Diagnostics raises €5 million to bring at-home molecular tests for Lyme disease and STIs to market appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
From Kickoff To First Concept: How To Turn Brand Strategy Into Visual Direction
17h ago
Slothful summer app lets you scroll simply by tilting your head
10h ago
Destructive Windows backdoor stuffs multiple wipers and ransomware code into a single package
13h ago
LisaFPGA brings Apple's magnificent misfire back in programmable logic
13h ago
New Lithuanian unicorn: Oxylabs ends bootstrapped streak after securing €113.6 million at €3.1 billion valuation
1d ago